185 related articles for article (PubMed ID: 21949774)
1. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
Atsou K; Chouaid C; Hejblum G
PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
[TBL] [Abstract][Full Text] [Related]
2. Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France.
Atsou K; Crequit P; Chouaid C; Hejblum G
PLoS One; 2016; 11(6):e0156514. PubMed ID: 27327159
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
5. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P; Leidl R; Holle R
Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial.
Li J; Hajek P; Pesola F; Wu Q; Phillips-Waller A; Przulj D; Myers Smith K; Bisal N; Sasieni P; Dawkins L; Ross L; Goniewicz ML; McRobbie H; Parrott S
Addiction; 2020 Mar; 115(3):507-517. PubMed ID: 31597207
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
10. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
11. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
13. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of the English smoking treatment services: evidence from practice.
Godfrey C; Parrott S; Coleman T; Pound E
Addiction; 2005 Apr; 100 Suppl 2():70-83. PubMed ID: 15844290
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of physical activity in the management of COPD patients in the UK.
Ramos M; Lamotte M; Gerlier L; Svangren P; Miquel-Cases A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2019; 14():227-239. PubMed ID: 30697043
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD.
Hoogendoorn M; Feenstra TL; Hoogenveen RT; Rutten-van Mölken MP
Thorax; 2010 Aug; 65(8):711-8. PubMed ID: 20685746
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
20. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]